__NUXT_JSONP__("/drugs/Lilotomab", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"1453362-55-4",chebiId:b,chemicalFormula:b,definition:"A murine immunoglobulin G1 (IgG1) monoclonal antibody directed against the CD37 antigen with potential antineoplastic activity. Upon administration, lilotomab both activates the immune system to induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against CD37-overexpressing tumor cells and induces apoptosis in these tumor cells. CD37 is a transmembrane glycoprotein expressed at high-levels on B-cells and to a lesser extent on T-cells and myeloid cells, and is frequently overexpressed in certain B-cell malignancies.",fdaUniiCode:"58I6YNR7BV",identifier:"C165685",preferredName:a,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C129822","C20401"],synonyms:["Anti-CD37 Monoclonal Antibody HH1","HH1","LILOTOMAB",a]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FLilotomab",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Lilotomab","","2021-10-30T13:35:45.473Z")));